Avid Bioservices Inc CDMO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDMO is a good fit for your portfolio.
News
-
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
-
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
-
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
-
Avid Bioservices to Participate at Upcoming Investor Conferences
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
Trading Information
- Previous Close Price
- $10.32
- Day Range
- $10.11–10.78
- 52-Week Range
- $4.07–13.24
- Bid/Ask
- $8.30 / $11.22
- Market Cap
- $650.43 Mil
- Volume/Avg
- 983,091 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 109.70
- Price/Sales
- 4.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 371
- Website
- https://www.avidbio.com
Comparables
Valuation
Metric
|
CDMO
|
IMVT
|
OTLK
|
---|---|---|---|
Price/Earnings (Normalized) | 109.70 | — | — |
Price/Book Value | 10.77 | 6.55 | — |
Price/Sales | 4.66 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CDMO
IMVT
OTLK
Financial Strength
Metric
|
CDMO
|
IMVT
|
OTLK
|
---|---|---|---|
Quick Ratio | 0.95 | 13.18 | 0.87 |
Current Ratio | 1.47 | 13.70 | 1.07 |
Interest Coverage | −5.21 | — | −71.52 |
Quick Ratio
CDMO
IMVT
OTLK
Profitability
Metric
|
CDMO
|
IMVT
|
OTLK
|
---|---|---|---|
Return on Assets (Normalized) | −1.92% | −44.70% | −209.78% |
Return on Equity (Normalized) | −5.11% | −49.06% | — |
Return on Invested Capital (Normalized) | −1.35% | −53.44% | −2,826.29% |
Return on Assets
CDMO
IMVT
OTLK
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Qrstpsjyj | Nskm | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Jfhrnymz | Jcnssvg | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Slvndprk | Wnfwfkl | $117.3 Bil | |||
Moderna Inc
MRNA
| Tgkzfqp | Wcgl | $46.1 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Hctlflhz | Phnpl | $29.7 Bil | |||
argenx SE ADR
ARGX
| Zkhkcypq | Kzysz | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Vvzkyppz | Mrrwh | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Yfztjff | Ycfcrw | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Wwwnjhzqb | Ynqf | $14.9 Bil | |||
Incyte Corp
INCY
| Scdgrldg | Npwkxq | $13.5 Bil |